Polyethylene glycol 400 and polyethylene glycol 600 are incorporated into aqueous and solvent-based film-coating dispersions as plasticizers for hydroxypropyl methylcellulose, polyvinyl alcohol–polyethylene glycol graft copolymer, and methacrylic acid copolymer film formers. The plasticizer lowers the minimum film-forming temperature of the dispersion; without this effect, coated tablets stored below the minimum film-forming temperature develop film brittleness, edge splitting, and logo bridging. In side-vented coating pans operating at drum differential pressures between -10 Pa and -50 Pa, PEG 400 is typically added at 10% to 30% w/w relative to dry polymer to balance film elongation against tackiness and core-to-core sticking. Incoming lots require verification against the USP-NF polyethylene glycol monograph for viscosity, pH, and average molecular weight because lot-to-lot viscosity shifts above 5% alter spray nozzle droplet size distribution and film thickness uniformity. When core residual moisture exceeds 4% w/w, film plasticization by PEG 400 can increase water vapor permeability and delay disintegration as measured by USP <701>. Equipment-based failures observed on production lines include nozzle clogging when PEG 400 is introduced as a cold liquid into a dispersion maintained below 15°C; the liquid is therefore pre-diluted 1:1 with purified water and metered under high-shear agitation. Coating dispersions containing PEG 600 show lower volatility and reduced pan wall deposition, but published failure data for polyvinyl alcohol–PEG interactions in high-speed pans with multiple spray guns remains limited; pilot-scale evaluation is required before linear scale-up.

Why Does Polyethylene Glycol 6000 Function as a Melt Binder in Granulation?

As a water-soluble meltable binder, PEG 6000 and PEG 8000 are processed in melt granulation and continuous twin-screw granulation lines to create interparticle bridges after cooling. The material is fed as solid flakes or pastilles, heated above its melting range of 55–60°C, and distributed as a low-viscosity liquid over the substrate particles; subsequent cooling to room temperature solidifies the bridges and produces granules with improved flow and compactability. The critical processing window is narrow because barrel temperatures exceeding 70°C can dissolve or partially amorphize low-melting active pharmaceutical ingredients, shifting dissolution profiles and causing capping during tableting. On a twin-screw granulator with an L/D ratio of 40:1, molten PEG 6000 is introduced through a liquid feed port downstream of the dry powder feed; screw speeds from 150 rpm to 300 rpm and barrel temperature profiles from 45°C to 65°C produce granules with bulk density generally between 0.45 g/cm³ and 0.60 g/cm³, depending on filler type and liquid feed rate. Residual moisture must be held below 1.5% w/w before melt granulation because steam generated at the binder–particle interface weakens granule strength and causes localized agglomeration. PEG 6000 at 5% to 10% w/w functions as a meltable binder, whereas 15% to 25% w/w produces larger granules that may retard disintegration unless crospovidone or croscarmellose sodium is added. Scale-up failures include torque spikes on the screw when the binder is injected at barrel temperatures below the melting range, solidifying on the screw shaft and vent port surfaces. Particle size distribution is analyzed by USP <786>; disintegration of the finished tablet is evaluated by USP <701>.

Capsule Shell Plasticization and Moisture Control in Oral Dosage Forms

Liquid-filled hard gelatin and soft gelatin capsule formulations use PEG 400 or PEG 600 as hygroscopic plasticizers or as part of the hydrophilic fill matrix. For hard gelatin shells, PEG at 10% to 20% w/w of the shell polymer mass reduces brittleness in storage below 40% relative humidity; above 30% w/w, plasticizer exudation and surface tack develop, causing aggregation on automatic capsule filling machines and in polishing drums. Soft gelatin shell compositions require adjustment of the plasticizer ratio with glycerin or sorbitol to maintain shell hardness under high-speed encapsulation; the processing room is controlled at 20–25°C and 35–50% RH because PEG 400 absorbs atmospheric moisture and changes shell water activity. The fill material is often a binary PEG 400/PEG 600 blend, selected to balance viscosity against leakage through the sealing bands; viscosity at 25°C is measured with a rotational viscometer according to USP <911> or USP <912>. Shell brittleness is assessed by a two-point bending test or an automated crush tester; batch acceptance should include the capsule disintegration test described in USP <701> because excessive plasticizer can prolong disintegration. Water activity of the shell and fill are measured with a dew-point hygrometer, with target values typically below 0.60 aw to limit microbial risk and crosslinking of gelatin over time. Published comparative data for PEG 600 in hydroxypropyl methylcellulose capsule shells is limited, and substitution into vegetarian capsules should not be based solely on gelatin capsule experience.

Parenteral dosage forms incorporate PEG 300 and PEG 400 as co-solvents for poorly water-soluble active pharmaceutical ingredients, but the selection boundary is not determined only by solubility. Hemolysis studies in the literature indicate significant erythrocyte lysis in some intravenous formulations when PEG 400 exceeds 40% v/v in direct contact; the exact threshold depends on species, contact time, formulation pH, and the presence of isotonic modifiers. The FDA Inactive Ingredient Database records route-specific maximum potency values for PEG 400 and PEG 300, with several injectable products listing PEG 400 up to 50% v/v, but higher levels require local irritation, hemolysis, and pharmacokinetic justification. Each parenteral lot must satisfy USP <85> for bacterial endotoxins, USP <788> for subvisible particulate matter, and USP <790> for visible particulates; osmolality is adjusted and verified according to USP <785>. Oxidative impurities are a critical control parameter: peroxide and aldehyde residues in PEG 300/400 can oxidize amine-containing APIs and form colored condensates, so stainless-steel transfer lines and nitrogen overlay are used during batch manufacture. Terminal sterilization by steam autoclaving at 121°C for 15 minutes can increase peroxide content; production-scale autoclaves often show shoulder temperature zones where the liquid does not reach the target F0, requiring validation with baffled vessels and load-mapping studies. PEG 400 is miscible with water and ethanol but incompatible with strong oxidizing agents and certain elastomeric stopper extracts; silicone tubing may absorb high-concentration PEG and alter filling set points.

When PEG 400 Replaces Propylene Glycol in Oral Liquid Vehicles

PEG 400 is introduced into oral solutions and suspensions when propylene glycol is restricted due to pediatric, geriatric, or formulation-specific considerations. The substitution is not rheologically or dielectrically equivalent because PEG 400 has higher viscosity, lower vapor pressure, and a different preservative-partitioning profile. In aqueous systems containing 20–30% v/v PEG 400, the dielectric constant decreases; this can reduce the solubility of ionizable APIs and shift pKa-dependent dissolution, so solubility should be reassessed rather than assumed equivalent to propylene glycol systems. Microbiological preservation is affected because PEG 400 can partition with parabens and reduce their aqueous activity; each changed formulation requires antimicrobial effectiveness testing according to USP <51>. On production filling lines, the higher viscosity at 25°C changes positive-displacement pump calibration and can reduce fill accuracy in multi-dose bottles; gravimetric check-weighing is increased during start-up. At concentrations above 50% v/v, the vehicle may become hyperosmotic and cause gastric upset; osmolarity is measured by USP <785> and adjusted with purified water. Storage in glass bottles is preferred because PEG 400 can extract plasticizers from PVC tubing and container closures. Published stability data for high-dose pediatric oral liquids using PEG 400 in place of propylene glycol is limited, so pilot-scale photostability and forced-degradation studies are required under ICH Q1B conditions.

PEGylation-Relevant Monodisperse Grade Selection for Conjugated APIs

Long-circulating injectable conjugates require polyethylene glycol or methoxypolyethylene glycol starting materials of defined molecular weight and end-group fidelity, typically in the range of 2,000 g/mol to 40,000 g/mol. The polydispersity index of the starting PEG API affects the molecular weight distribution of the final conjugate; release specifications therefore include size-exclusion chromatography and matrix-assisted laser desorption ionization time-of-flight mass spectrometry to confirm the distribution. For injectable PEGylated proteins, batch records require free PEG content below a product-specific threshold, residual peroxide below the pharmacopoeial limit, and high-molecular-weight aggregate content below 0.1% by size-exclusion HPLC. The conjugation step uses activated PEG esters, carbonates, or maleimides; residual water in the PEG starting material above 0.5% w/w consumes the activated functional group and lowers conjugation yield. During lyophilization, cake collapse is observed when PEG content exceeds 50% w/w of the solid; annealing at -20°C for 4 hours and the use of tertiary butyl alcohol–water solvent systems are common process adjustments. Final sterile filtration through 0.22 µm membrane filters requires membrane compatibility studies because high-molecular-weight PEG adsorbs to some nylon membranes and reduces protein recovery. Finished-product release for therapeutic recombinant protein injections follows USP <787>; pharmacopoeial monographs for PEGylated conjugates remain product-specific rather than generic.